JP2017526655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526655A5 JP2017526655A5 JP2017504772A JP2017504772A JP2017526655A5 JP 2017526655 A5 JP2017526655 A5 JP 2017526655A5 JP 2017504772 A JP2017504772 A JP 2017504772A JP 2017504772 A JP2017504772 A JP 2017504772A JP 2017526655 A5 JP2017526655 A5 JP 2017526655A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- nanostructured biocompatible
- hydrophobic polymer
- nanostructured
- biocompatible wafer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 18
- 229920001600 hydrophobic polymer Polymers 0.000 claims 14
- 239000000835 fiber Substances 0.000 claims 12
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 239000003405 delayed action preparation Substances 0.000 claims 6
- 239000011859 microparticle Substances 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 3
- 229920002807 Thiomer Polymers 0.000 claims 3
- 229920002988 biodegradable polymer Polymers 0.000 claims 3
- 239000004621 biodegradable polymer Substances 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000002086 nanomaterial Substances 0.000 claims 3
- -1 polyethylene Polymers 0.000 claims 3
- 229920001285 xanthan gum Polymers 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 claims 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004698 Polyethylene Substances 0.000 claims 2
- 239000004743 Polypropylene Substances 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 229940124350 antibacterial drug Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 229920000573 polyethylene Polymers 0.000 claims 2
- 239000004626 polylactic acid Substances 0.000 claims 2
- 229920001155 polypropylene Polymers 0.000 claims 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- ZJFVZKMCIRCNAN-UHFFFAOYSA-N 2-[2-[3-[2-(2-aminoethoxy)ethoxy]-2,2-bis[2-(2-aminoethoxy)ethoxymethyl]propoxy]ethoxy]ethanamine Chemical compound NCCOCCOCC(COCCOCCN)(COCCOCCN)COCCOCCN ZJFVZKMCIRCNAN-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000029910 Anterior chamber disease Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960002470 bimatoprost Drugs 0.000 claims 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 1
- 229960000722 brinzolamide Drugs 0.000 claims 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 1
- 229960003655 bromfenac Drugs 0.000 claims 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960001469 fluticasone furoate Drugs 0.000 claims 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 229960001798 loteprednol Drugs 0.000 claims 1
- 229960003744 loteprednol etabonate Drugs 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 229960003128 mupirocin Drugs 0.000 claims 1
- 229930187697 mupirocin Natural products 0.000 claims 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims 1
- 229960001002 nepafenac Drugs 0.000 claims 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 1
- 229960000808 netilmicin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims 1
- 229960004740 voriconazole Drugs 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021160573A JP2022001582A (ja) | 2014-09-06 | 2021-09-30 | 眼において薬物徐放を達成する方法及び生体適合性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046918P | 2014-09-06 | 2014-09-06 | |
| US62/046,918 | 2014-09-06 | ||
| PCT/US2015/048795 WO2016037169A1 (en) | 2014-09-06 | 2015-09-08 | Methods and biocompatible compositions to achieve sustained drug release in the eye |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160573A Division JP2022001582A (ja) | 2014-09-06 | 2021-09-30 | 眼において薬物徐放を達成する方法及び生体適合性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526655A JP2017526655A (ja) | 2017-09-14 |
| JP2017526655A5 true JP2017526655A5 (enExample) | 2018-08-30 |
| JP7026507B2 JP7026507B2 (ja) | 2022-02-28 |
Family
ID=55440434
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504772A Active JP7026507B2 (ja) | 2014-09-06 | 2015-09-08 | 眼において薬物徐放を達成する方法及び生体適合性組成物 |
| JP2021160573A Withdrawn JP2022001582A (ja) | 2014-09-06 | 2021-09-30 | 眼において薬物徐放を達成する方法及び生体適合性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160573A Withdrawn JP2022001582A (ja) | 2014-09-06 | 2021-09-30 | 眼において薬物徐放を達成する方法及び生体適合性組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9931306B2 (enExample) |
| EP (1) | EP3188688B1 (enExample) |
| JP (2) | JP7026507B2 (enExample) |
| KR (1) | KR102456032B1 (enExample) |
| CN (2) | CN106604695B (enExample) |
| AU (2) | AU2015311637B2 (enExample) |
| CA (1) | CA2960213C (enExample) |
| ES (1) | ES2900025T3 (enExample) |
| MY (1) | MY178327A (enExample) |
| SG (1) | SG11201701714RA (enExample) |
| WO (1) | WO2016037169A1 (enExample) |
| ZA (2) | ZA201701467B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9931306B2 (en) * | 2014-09-06 | 2018-04-03 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
| WO2017062770A1 (en) * | 2015-10-08 | 2017-04-13 | Silverberg Noah | Punctal plug and bioadhesives |
| CA3038115A1 (en) * | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| WO2018067882A1 (en) | 2016-10-05 | 2018-04-12 | Titan Pharmaceuticals, Inc. | Implantable devices for drug delivery with reduced burst release |
| EP3630024B1 (en) * | 2017-05-22 | 2022-04-06 | California Institute of Technology | Small molecule transport device with anti-condensation filler for drug delivery or waste removal |
| JP2020527591A (ja) * | 2017-07-17 | 2020-09-10 | ウルフクリーク バイオテック プライベート リミテッド | 活性薬剤送達のための微粒子製剤 |
| JP7373207B2 (ja) | 2018-03-01 | 2023-11-02 | バー‐イラン、ユニバーシティー | 眼の状態の矯正に使用するためのシステム、方法、及び材料組成物 |
| MA52774A (fr) * | 2018-06-05 | 2021-04-14 | Corneat Vision Ltd | Timbre de greffe ophtalmique synthétique |
| CN109853054A (zh) * | 2019-02-27 | 2019-06-07 | 上海交通大学医学院附属第九人民医院 | 一种同轴静电纺丝三维打印生物支架的装置及搭建方法 |
| EP3701974B1 (en) * | 2019-02-28 | 2024-08-28 | Agency for Science, Technology and Research | A material suitable for use as a vitreous substitute and related methods |
| CA3132635A1 (en) * | 2019-03-05 | 2020-09-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical compositions for treating ocular diseases or disorders |
| WO2020198798A1 (en) * | 2019-04-02 | 2020-10-08 | Cytomatrix Limited | A composition for the delivery of biologically active agents and uses thereof |
| TWI826685B (zh) | 2019-05-02 | 2023-12-21 | 瑞士商愛爾康公司 | 可溶解聚合物眼睛插入物及其使用方法 |
| CA3149866A1 (en) | 2019-10-24 | 2021-04-29 | Denis E. Labombard | Ocular device and drug delivery system, with case |
| BR112022011067A2 (pt) * | 2019-12-10 | 2022-08-23 | Alcon Inc | Insertos oculares poliméricos dissolvíveis com um polímero biodegradável |
| EP4142664A4 (en) * | 2020-04-27 | 2024-05-29 | Ocular Therapeutix, Inc. | METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS |
| KR102467288B1 (ko) * | 2020-06-09 | 2022-11-17 | 동국대학교 산학협력단 | 결막 접촉용 약물 전달기 |
| EP3928805A1 (en) * | 2020-06-26 | 2021-12-29 | Royal College of Surgeons in Ireland | A device for use in the delivery of an active agent |
| US20220160668A1 (en) * | 2020-11-23 | 2022-05-26 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
| WO2022250977A1 (en) * | 2021-05-26 | 2022-12-01 | The Texas A&M University System | Biodegradable mucoadhesive pharmaceutical formulations and methods thereof |
| CN114869862A (zh) * | 2022-04-24 | 2022-08-09 | 温州医科大学附属眼视光医院 | 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法 |
| AU2024330194A1 (en) * | 2023-08-31 | 2026-04-02 | University Of Tennessee Research Foundation | Sustained release ocular implants |
| TW202547517A (zh) * | 2024-06-06 | 2025-12-16 | 美商視爾普斯眼科公司 | 用於治療眼部疾病之組合物及方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
| US5177168A (en) * | 1989-10-17 | 1993-01-05 | Polymer Technology Corp. | Polymeric compositions useful in oxygen permeable contact lenses |
| JPH10509696A (ja) | 1994-10-12 | 1998-09-22 | フォーカル， インコーポレイテッド | 生分解性ポリマーを介する標的化送達 |
| US8273366B2 (en) | 2002-06-05 | 2012-09-25 | University Of Florida Research Foundation, Incorporated | Ophthalmic drug delivery system |
| CA2601864A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease |
| CA2609687C (en) * | 2005-05-24 | 2014-04-22 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
| AU2006348901C1 (en) * | 2006-09-28 | 2013-11-14 | Essity Hygiene And Health Aktiebolag | Absorbent article, belt structure, manufacturing method for a belt structure and manufacturing method for an absorbent article |
| US8614103B2 (en) * | 2006-10-27 | 2013-12-24 | Lpath, Inc. | Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions |
| CA2670944A1 (en) * | 2006-12-18 | 2008-06-26 | Alcon Research, Ltd. | Devices and methods for ophthalmic drug delivery |
| US8974814B2 (en) * | 2007-11-12 | 2015-03-10 | California Institute Of Technology | Layered drug delivery polymer monofilament fibers |
| US8361492B2 (en) * | 2008-04-29 | 2013-01-29 | Ocugenics, LLC | Drug delivery system and methods of use |
| US8083347B2 (en) | 2008-04-29 | 2011-12-27 | Ocugenics, LLC | Drug delivery system and methods of use |
| US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US20100291182A1 (en) | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
| JP5890182B2 (ja) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| US8961600B2 (en) * | 2009-06-25 | 2015-02-24 | Optonol Ltd. | Method of using a fiber matrix for maintaining space in soft tissues |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US20110229551A1 (en) * | 2010-03-17 | 2011-09-22 | Notus Laboratories, Inc. | Drug delivery compositions and methods using nanofiber webs |
| US9028860B2 (en) * | 2010-04-28 | 2015-05-12 | Poly-Med, Inc. | Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery |
| WO2012114138A1 (fr) * | 2011-02-21 | 2012-08-30 | Cerebel-Invest Sa | Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active |
| EP3494959A3 (en) | 2011-04-29 | 2019-09-11 | Allergan, Inc. | Sustained release latanoprost implant |
| CA2848397C (en) | 2011-09-14 | 2022-04-26 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
| CN203089455U (zh) * | 2013-02-01 | 2013-07-31 | 浙江大学医学院附属第二医院 | 襻上镶嵌有药物缓释微囊的人工晶状体 |
| US9931306B2 (en) * | 2014-09-06 | 2018-04-03 | Integral Biosystems Llc | Methods and biocompatible compositions to achieve sustained drug release in the eye |
-
2015
- 2015-09-08 US US15/509,083 patent/US9931306B2/en active Active
- 2015-09-08 CA CA2960213A patent/CA2960213C/en active Active
- 2015-09-08 EP EP15838075.8A patent/EP3188688B1/en active Active
- 2015-09-08 CN CN201580047771.9A patent/CN106604695B/zh active Active
- 2015-09-08 AU AU2015311637A patent/AU2015311637B2/en active Active
- 2015-09-08 MY MYPI2017700768A patent/MY178327A/en unknown
- 2015-09-08 SG SG11201701714RA patent/SG11201701714RA/en unknown
- 2015-09-08 JP JP2017504772A patent/JP7026507B2/ja active Active
- 2015-09-08 CN CN201811209851.1A patent/CN109481447A/zh active Pending
- 2015-09-08 KR KR1020177006261A patent/KR102456032B1/ko active Active
- 2015-09-08 ES ES15838075T patent/ES2900025T3/es active Active
- 2015-09-08 WO PCT/US2015/048795 patent/WO2016037169A1/en not_active Ceased
-
2017
- 2017-02-27 ZA ZA2017/01467A patent/ZA201701467B/en unknown
- 2017-08-25 ZA ZA2017/05792A patent/ZA201705792B/en unknown
-
2018
- 2018-04-03 US US15/944,065 patent/US10328033B2/en active Active
-
2019
- 2019-10-16 AU AU2019250153A patent/AU2019250153B2/en active Active
-
2021
- 2021-09-30 JP JP2021160573A patent/JP2022001582A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019250153B2 (en) | Methods and biocompatible compositions to achieve sustained drug release in the eye | |
| JP5415262B2 (ja) | 活性剤送達用の涙点プラグ | |
| ES2834964T3 (es) | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida | |
| JP6100782B2 (ja) | 緑内障および高眼圧症を治療するための活性剤の徐放送達 | |
| ES2624448T3 (es) | Implantes poliméricos de agonistas alfa-2 adrenérgicos biodegradables | |
| RU2440102C2 (ru) | Системы доставки лекарственного средства внутрь глаза | |
| JP5596122B2 (ja) | 涙点プラグ | |
| CN102123713A (zh) | 治疗青光眼和眼高血压的活性剂的持续释放递送 | |
| AU2016231616A1 (en) | Intraocular sustained release drug delivery systems and methods for treating ocular conditions | |
| CN102105118A (zh) | 青光眼的联合治疗 | |
| TR201802759T4 (tr) | Prostamid içeren intraoküler implantlar ve kullanım yöntemleri. | |
| CN101505696A (zh) | 用于递送活性试剂的泪点塞 | |
| JP6213560B2 (ja) | 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法 | |
| NZ729467B2 (en) | Methods and biocompatible compositions to achieve sustained drug release in the eye | |
| Li | Moxifloxacin loaded ophthalmic inserts for prophylaxis of endophthalmitis | |
| HK1235660B (en) | Methods and biocompatible compositions to achieve sustained drug release in the eye |